Three winners of the long-term biotech boom
Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management teams and fair valuations.
The biotechnology sector has been instrumental in bringing Covid-19 under control. It was not the traditional large pharmaceutical vaccine specialists that led the way, but the innovative biotech firms such as BioNTech and Moderna. These companies have turned a much-discussed idea – vaccines based on RNA, a new approach – into a product and have manufactured millions of doses. That has led to valuations of some of the innovative small-cap companies accelerating to eye-wateringly high levels.
It is easy to get caught up in the hype of investing in stocks with rapidly rising share prices. However, we rely on fundamental analysis in making our investment decisions and look out for companies that boast a compelling roster of innovative products. We also ensure that these companies have experienced managers to help the business deliver long-term growth. We also seek out stocks that are fairly valued and we do not chase overhyped small-cap biotechs. In our opinion, these three stocks have good pipelines, strong management teams and fair valuations.
Orphan diseases: a high-growth niche
The experienced management team at Horizon Therapeutics (Nasdaq: HZNP) has turned the company into a high-growth “orphan disease” specialist. Orphan diseases affect a small number of patients, but still command good pricing power and favourable patent protections.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
One of the company’s current drugs is Tepezza, used to treat a rare condition called thyroid eye disease. The launch of this drug has been very successful, with peak sales estimated to exceed $3bn. In February 2021, in order to maintain its pipeline of new drugs, the company bought another orphan-disease company called Viela Bio.
Tackling multiple maladies
Alnylam Pharmaceuticals (Nasdaq: ALNY) has developed an RNA-platform technology that can regulate the production of various protein cells to help treat a number of different diseases. There are currently four drugs approved, which help to treat diseases caused by genetic mutations, in addition to a broad, growing, and therapeutically diversified pipeline of projects with the potential for high sales.
The company is adapting this technology to treat a range of other diseases. Some of these conditions are also caused by genetic abnormalities, while more common ailments such as hepatitis B and hypertension will also be tackled.
Shifting from HIV to cancer
Gilead Sciences (Nasdaq: GILD) is a mature biotech that built its business on HIV treatments. In 2011 it acquired Pharmasset, which had a pipeline drug to treat and cure hepatitis-C infections. The hepatitis-C franchise became hugely successful, generating peak sales of $10bn. But its growth rate dwindled soon after, as patients left treatment once they were cured.
Since then, a new management team has refocused the company on oncology by acquiring Immunomedics for $21bn. The jury is still out as to whether this acquisition will be considered a success; it depends on the data from a large breast-cancer study expected to be made public later in 2021. Gilead Sciences has not taken part in the recent market rally as it is considered defensive, so it is trading on a relatively low-price earnings (p/e) multiple.
-
Goodwin: A superlative British manufacturer to buy nowVeteran engineering group Goodwin has created a new profit engine. But following its tremendous run, can investors still afford the shares?
-
Is US stock market exceptionalism over?US stocks trailed the rest of the world in 2025. Is this a sign that a long-overdue shift is underway?
-
Goodwin: A superlative British manufacturer to buy now
Veteran engineering group Goodwin has created a new profit engine. But following its tremendous run, can investors still afford the shares?
-
A change in leadership: Is US stock market exceptionalism over?
US stocks trailed the rest of the world in 2025. Is this a sign that a long-overdue shift is underway?
-
A reckoning is coming for unnecessary investment trustsInvestment trusts that don’t use their structural advantages will find it increasingly hard to survive, says Rupert Hargreaves
-
Metals and AI power emerging marketsThis year’s big emerging market winners have tended to offer exposure to one of 2025’s two winning trends – AI-focused tech and the global metals rally
-
8 of the best houses for sale with beautiful fireplacesThe best houses for sale with beautiful fireplaces – from a 15th-century cottage in Kent to a 17th-century palazzo in Oxfordshire
-
King Copper’s reign will continue – here's whyFor all the talk of copper shortage, the metal is actually in surplus globally this year and should be next year, too
-
Luana Lopes Lara: The ballerina who made a billion from prediction marketsLuana Lopes Lara trained at the Bolshoi, but hung up her ballet shoes when she had the idea of setting up a business in the prediction markets. That paid off
-
British blue chips offer investors reliable income and growthOpinion Ben Russon, portfolio manager and co-head UK equities, ClearBridge Investments, highlights three British blue chips where he'd put his money
